Hematologic Malignancy
Indolent Systemic Mastocytosis
CI-CAN-00007849ISMExplore in graph →
HematologicNon-malignant3 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00007849ISMExplore in graph →
Clinical trials
15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04655118 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | unknown | Phase 2 | 121 | Telios Pharma, Inc.INDUSTRY | 13 | May 10, 2024 | clinicaltrials |
| NCT01920204 | Midostaurin in Indolent Systemic Mastocytosis | unknown | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Jan 19, 2015 | clinicaltrials |
Data updated 22 days agoSource updated May 10, 2024source: clinicaltrials